Owen Hughes is the Chief Executive Officer of Sail Bio, Inc., a privately held company founded in 2022.  His operational experience includes prior roles as Chief Executive Officer, Co-Founder, and member of the Board of Directors of Cullinan Oncology and as Chief Business Officer and Head of Corporate Development at Intarcia Therapeutics, Inc.  Mr. Hughes also brings 15 years in healthcare finance experience to XOMA, including roles as Director at Bain Capital, LP, and Portfolio Manager at Pyramis Global Advisors LLC, a Fidelity Investments Company.  He currently serves as the Chairman of the Board of Directors of Ikena Oncology and was the former Chairman of Radius Health and Lead Independent Director of Translate Bio until their sale to Gurnet Point Capital and Sanofi, respectively.  Mr. Hughes holds a Bachelor’s in History from Dartmouth College.

Tom Burns, Senior Vice President, Finance and Chief Financial Officer, joined XOMA in August 2006 and has held various senior finance and accounting roles. He is responsible for all financial matters affecting or involving the XOMA companies, including directing XOMA's financial strategy, accounting, budgeting, financial planning and analysis and investor relations functions. Mr. Burns has 20 years of experience in accounting and finance in both biotechnology and high technology companies. Prior to XOMA, he held multiple senior financial management positions at high-tech companies including Mattson Technology, IntruVert Networks (acquired by McAfee), Niku Corporation (acquired by Computer Associates) and Conner Technology. Mr. Burns received his Bachelor's degree from Santa Clara University and his Masters of Business Administration from Golden Gate University.

Brad Sitko, XOMA’s Chief Investment Officer, joined the company in 2023, bringing deep expertise in royalty monetizations as an investor, investment banker, and strategy consultant. Mr. Sitko brings over 20 years of diverse life sciences experience to XOMA including investing, capital raising, corporate strategy, BD&L, and M&A. He’s executed more than 40 transactions, accounting for over $8B of M&A volume, capital raised, and royalties monetized.

Mr. Sitko joins XOMA from RTW Investments, a leading life sciences investment firm, where he led the firm's royalty transactions. He also served as a member of the Board of the firm’s ICAV and was the founding Chief Financial Officer of its incubated Shanghai-based biopharma company.

Mr. Sitko previously was a senior executive at DNAnexus, scaling the company’s operations globally and growing its industry leading B2B genomics platform. Prior to that, he was a senior investment banker at MTS Health Partners, advising clients on royalty monetization and structured finance, capital raising and M&A. Mr. Sitko began his career as a strategy consultant at Frankel Group (now part of Oliver Wyman) where he advised biopharma companies on strategic planning, commercial launches, and business development strategies.

Mr. Sitko earned a B.A. from University of Pennsylvania and an MBA from Columbia Business School.